Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral viscous budesonide in eosinophilic esophagitis after esophageal atresia repair
2019-002691-14Phase 2Completed
- Sponsor
- Ospedale Pediatrico Bambino Gesù
- Start
- May 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of budesonide in eosinophilic esophagitis (EoE), sponsored by Ospedale Pediatrico Bambino Gesù. Primary endpoint: Histological response after 12 weeks of therapy. Started May 2021; status: completed.
02
Drugs
budesonide
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on 2019-002691-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002691-14.